LivaNova Q4 revenue, EPS tops expectations on cardiopulmonary market demand

Livanova

25/02/2026 11:12

Overview

Medical technology firm's Q4 revenue rose 12.1%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company received FDA approval for cloud-based digital health platform

Outlook

LivaNova expects 2026 revenue growth between 6.0% and 7.0% on a constant-currency basis

Company projects 2026 adjusted EPS between $4.15 and $4.25

Provider reimbursement for VNS Therapy procedures to increase significantly in 2026

Result Drivers

CARDIOPULMONARY DEMAND - Strong consumables demand and Essenz Perfusion System sales drove Cardiopulmonary revenue growth

VNS THERAPY REIMBURSEMENT - Increased Medicare reimbursement for VNS Therapy procedures is expected to reduce barriers to procedure penetration

FDA APPROVAL - FDA approval for cloud-based digital health platform enhances insights into patient journey

Company press release: ID:nBw745t3Ma

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$360.90 mln
$353.31 mln (9 Analysts)
Q4 Adjusted EPS
Beat
$0.86
$0.82 (10 Analysts)
Q4 EPS
$0.56


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for LivaNova PLC is $70.00, about 1.4% above its February 24 closing price of $69.05

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 13 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)